Paediatric pulmonary embolism: a pathway to improved outcomes
Publication date: Available online 13 February 2019Source: The Lancet HaematologyAuthor(s): Vera Ignjatovic (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 14, 2019 Category: Hematology Source Type: research

Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study
Publication date: Available online 13 February 2019Source: The Lancet HaematologyAuthor(s): Marie-Claude Pelland-Marcotte, Catherine Tucker, Alicia Klaassen, Maria Laura Avila, Ali Amid, Nour Amiri, Suzan Williams, Jacqueline Halton, Leonardo R BrandãoSummaryBackgroundLittle is known about severe pulmonary embolism in children. We aimed to report pulmonary embolism outcomes, identify risk factors for unfavourable outcomes, and evaluate the discriminative ability of two clinical-severity indices in children.MethodsIn this retrospective cohort study, we included consecutive patients aged 18 years or younger with acute...
Source: The Lancet Haematology - February 14, 2019 Category: Hematology Source Type: research

Frailty in multiple myeloma: the need for harmony to prevent doing harm
Publication date: Available online 6 February 2019Source: The Lancet HaematologyAuthor(s): Sonja Zweegman, Alessandra Larocca (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 7, 2019 Category: Hematology Source Type: research

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
Publication date: Available online 6 February 2019Source: The Lancet HaematologyAuthor(s): Gordon Cook, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Vallari Shah, Martin F Kaiser, Sarah R Brown, Walter M Gregory, J Anthony Child, Faith E Davies, Gareth J Morgan, David A Cairns, Graham H JacksonSummaryBackgroundTolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall survival in patients with multiple myeloma who were ineligible for stem-cell transplantatio...
Source: The Lancet Haematology - February 7, 2019 Category: Hematology Source Type: research

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
We report unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension.MethodsIn the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned (1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 120 mg/kg with either total body irradiation (12 Gy) or busu...
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

To treat, or not to treat: the dilemma for pregnant women
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Is venous thromboembolism a problem in patients with cancer in palliative care?
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Per Morten Sandset, Anders E A Dahm (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

In-vivo T-cell depletion: burden of morbidity versus survival
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Mary Eapen (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Stefano Molica, Emili Montserrat (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Clare White, Simon I R Noble, Max Watson, Flavia Swan, Victoria L Allgar, Eoin Napier, Annmarie Nelson, Jayne McAuley, Jennifer Doherty, Bernadette Lee, Miriam J JohnsonSummaryBackgroundThe prevalence of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is unknown whether current international thromboprophylaxis guidance is applicable to this population. We aimed to determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care units (SPCUs).MethodsWe...
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H FowlerSummaryBackgroundTherapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.Methods...
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?
Publication date: Available online 29 January 2019Source: The Lancet HaematologyAuthor(s): Rena Buckstein (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 29, 2019 Category: Hematology Source Type: research

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia.MethodsIn this randomised, double-blind, phase 2 study, treatment-naive patients were recruited from clinical centres across 10 countries (Australia, Belgium, Canada, Greece, Hungary, Israel, South Korea, Poland, Russia, and the USA). Patients with acute myeloid leukaemia of any subtype except M3 and M7 were stratified by antecedent malignant haematological disorder (yes or no) and age (18–60 years or>60 years) and were then randomly assigned (1:1) using ...
Source: The Lancet Haematology - January 29, 2019 Category: Hematology Source Type: research

BTK/PD-1 blockade for treatment of Richter's transformation
Publication date: Available online 11 January 2019Source: The Lancet HaematologyAuthor(s): Pek Sang Tang, Constantine S Tam (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 12, 2019 Category: Hematology Source Type: research

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Publication date: Available online 11 January 2019Source: The Lancet HaematologyAuthor(s): Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigón, Andrzej Hellmann, Bryone Kuss, David D F Ma, Fatih Demirkan, Münci Yağci, Netanel A Horowitz, Paula Marlton, Raul Cordoba, Tomasz WrobelSummaryBackgroundPreclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrut...
Source: The Lancet Haematology - January 12, 2019 Category: Hematology Source Type: research

Closing in on targeted therapy for acute myeloid leukaemia
Publication date: January 2019Source: The Lancet Haematology, Volume 6, Issue 1Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 5, 2019 Category: Hematology Source Type: research

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma
Publication date: January 2019Source: The Lancet Haematology, Volume 6, Issue 1Author(s): Stephen M Ansell (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 5, 2019 Category: Hematology Source Type: research

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
This study is registered with ClinicalTrials.gov, number NCT03114683, and is ongoing.FindingsBetween April 19, 2017, and Nov 1, 2017, 96 patients were enrolled and commenced treatment. Four patients, whose diagnosis was not subsequently confirmed by the central pathology laboratory, were excluded from the full analysis set. Ten patients discontinued treatment. Median duration of follow-up was 10·5 months. In the full analysis set (n=92), 74 patients (80·4%; 95% CI 70·9–88·0) had an IRRC-assessed objective response before the analysis cutoff date of April 16, 2018. 89 (93%) of 96 patients h...
Source: The Lancet Haematology - January 5, 2019 Category: Hematology Source Type: research

The best direct-acting oral anticoagulant for treatment of venous thromboembolism?
Publication date: Available online 14 December 2018Source: The Lancet HaematologyAuthor(s): Corinne Frere, Dominique Farge (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 15, 2018 Category: Hematology Source Type: research

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
Publication date: Available online 14 December 2018Source: The Lancet HaematologyAuthor(s): Matthew S Davids, Haesook T Kim, Alyssa Nicotra, Alexandra Savell, Karen Francoeur, Jeffrey M Hellman, Josie Bazemore, Hari P Miskin, Peter Sportelli, Laura Stampleman, Rodrigo Maegawa, Jens Rueter, Adam M Boruchov, Jon E Arnason, Caron A Jacobson, Eric D Jacobsen, David C Fisher, Jennifer R Brown, Blood Cancer Research Partnership of the Leukemia and Lymphoma SocietySummaryBackgroundPatients with relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit from ibrutinib...
Source: The Lancet Haematology - December 15, 2018 Category: Hematology Source Type: research

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
Publication date: Available online 14 December 2018Source: The Lancet HaematologyAuthor(s): Ghadeer K Dawwas, Joshua Brown, Eric Dietrich, Haesuk ParkSummaryBackgroundApixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles. Differences in the risk of recurrent venous thromboembolism and major bleeding events between the two drugs are currently unknown. We aimed to compare the effectiveness and safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism and major b...
Source: The Lancet Haematology - December 15, 2018 Category: Hematology Source Type: research

Concurrent treatment with two B-cell receptor pathway inhibitors
Publication date: Available online 14 December 2018Source: The Lancet HaematologyAuthor(s): Tadeusz Robak (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 15, 2018 Category: Hematology Source Type: research

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Publication date: Available online 10 December 2018Source: The Lancet HaematologyAuthor(s): Nicholas J Short, Hagop M Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M Kadia, Naval Daver, Maro Ohanian, Courtney D Dinardo, Zeev Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B Benton, Prithviraj Bose, Yesid Alvarado, Elias Jabbour, Steven M Kornblau, Naveen Pemmaraju, Nitin JainSummaryBackgroundHypomethylating agents, such as decitabine, are the standard of care for older patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have suggested that a 10-day schedule of...
Source: The Lancet Haematology - December 11, 2018 Category: Hematology Source Type: research

10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck
Publication date: Available online 10 December 2018Source: The Lancet HaematologyAuthor(s): Amanda F Cashen (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 11, 2018 Category: Hematology Source Type: research

Characterisation of rare haematological immune-related toxicities
Publication date: Available online 4 December 2018Source: The Lancet HaematologyAuthor(s): John B Haanen, Solange Peters (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 5, 2018 Category: Hematology Source Type: research

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1.MethodsIn this descriptive observational study, we included consecutive patients aged at least 18 years with grade 2 or worse haem-irAEs induced by anti-PD-1 or anti-PD-L1 immunotherapy registered in three French pharmacovigilance databases: the Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC; a prospective registry of patients treated with anti-PD-1 or anti-PD-L1 at a single centre), the ImmunoTOX committee of Gustave Roussy (a nat...
Source: The Lancet Haematology - December 5, 2018 Category: Hematology Source Type: research

The humanitarian cost of Yemen's crumbling health system
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Intensive immunochemotherapy for high-risk aggressive B-cell lymphomas: MYC-rearrangements and beyond
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Eric D Hsi (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

A step ahead in Philadelphia chromosome-positive acute lymphoblastic leukaemia
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Josep-Maria Ribera (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

The forgotten class of drugs for multiple myeloma: HDAC inhibitors
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Noa Biran, David S Siegel, David H Vesole (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Oliver Ottmann (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Correction to Lancet Haematol 2017; 4: e431–42
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Correction to Lancet Haematol 2018; 5: e422–29
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
This study is registered with ClinicalTrials.gov (NCT01092182).Findings53 patients were enrolled, with median age of 61 years (range 29–80; IQR 50–70); 43 (81%) patients had stage III–IV disease and 26 (49%) had high-intermediate or high international prognostic index (IPI) scores. 19 patients had confirmed MYC rearrangement alone (single-hit) and 24 also had rearrangement of BCL2, BCL6, or both (double-hit), with similar characteristics between these two groups. After a median follow-up of 55·6 months (IQR 50·5–61·1), 48-month event-free survival was 71·0% (95% CI 56&mid...
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Elias Jabbour, Nicholas J Short, Farhad Ravandi, Xuelin Huang, Naval Daver, Courtney D DiNardo, Marina Konopleva, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Koji Sasaki, Jorge Cortes, Rebecca Garris, Joseph D Khoury, Jeffrey Jorgensen, Nitin Jain, Joie Alvarez, Susan O'Brien, Hagop KantarjianSummaryBackgroundThe combination of chemotherapy and ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukaemia has the potential to be a new standard of care for the disease; however, long-term efficacy and safe...
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Elisabet E Manasanch, Jatin J Shah, Hans C Lee, Donna M Weber, Sheeba K Thomas, Behrang Amini, Lei Feng, Zuzana Berkova, Michelle Hildebrandt, Robert Z OrlowskiSummaryBackgroundBortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the front-line treatment of multiple myeloma. Panobinostat is approved in combination with bortezomib and dexamethasone in patients with myeloma who 'have been given at least two previous regimens including bortezomib and an immunomodulatory agent. We aimed to determine the maximum...
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial
Publication date: December 2018Source: The Lancet Haematology, Volume 5, Issue 12Author(s): Andrea Biondi, Virginie Gandemer, Paola De Lorenzo, Gunnar Cario, Myriam Campbell, Anders Castor, Rob Pieters, André Baruchel, Ajay Vora, Veronica Leoni, Jan Stary, Gabriele Escherich, Chi-Kong Li, Giovanni Cazzaniga, Hélène Cavé, Jutta Bradtke, Valentino Conter, Vaskar Saha, Martin Schrappe, Maria Grazia ValsecchiSummaryBackgroundThe EsPhALL2004 randomised trial showed a 10% advantage in disease-free survival for short, discontinuous use of imatinib after induction compared with no use of imatinib in pat...
Source: The Lancet Haematology - November 29, 2018 Category: Hematology Source Type: research

Embracing the complexity in cancer therapy
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Histological transformation and secondary malignancies in follicular lymphoma
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Umberto Vitolo, Annalisa Chiappella (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Is pharmacokinetic guidance a must in busulfan regimens?
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Yoshinobu Kanda (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Biosimilars: when a negative study can be positive
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Brian K Link (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Exercise training: a prescription for sickle-cell disease?
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Gregory J Kato (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Takashi Watanabe, Kensei Tobinai, Masashi Wakabayashi, Yasuo Morishima, Hirofumi Kobayashi, Tomohiro Kinoshita, Takayo Suzuki, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Masafumi Taniwaki, Naokuni Uike, Tadashi Yoshino, Sigeru Nawano, Takashi Terauchi, Tomomitsu Hotta, Hirokazu Nagai, Kunihiro Tsukasaki, Mitsutoshi Kurosawa, Kayo YamagishiSummaryBackgroundStandard treatment for untreated advanced-stage follicular lymphoma is rituximab plus chemotherapy. The incidence of histological transformation of follicular lymphoma has be...
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
This study is registered with ClinicalTrials.gov, number NCT01572662.FindingsBetween April 18, 2012, and Dec 9, 2015, 98 patients were enrolled. 49 patients were randomly assigned to the 16K group and 49 to the 20K group, one of which was removed from the study before starting the intervention. Median age was 60 years (IQR 54–67). 50 (52%) patients had an HCT-specific comorbidity index score of 3 or more, and 41 (42%) had a high or very high Disease Risk Index score. Day 100 non-relapse mortality was 4% (95% CI 0–10) in the 16K group and 6% (0–13) in the 20K group (p=0·65). Infection was the most c...
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Anne Lennard, José Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yañez Ruiz, Marek Trneny, Leslie Popplewell, Bertrand Coiffier, Christian Buske, Won-Seog KimSummaryBackgroundStudies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharm...
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complications (EXDRE): an open-label randomised controlled trial
Publication date: November 2018Source: The Lancet Haematology, Volume 5, Issue 11Author(s): Barnabas Gellen, Laurent A Messonnier, Frédéric Galactéros, Etienne Audureau, Angèle N Merlet, Thomas Rupp, Sandrine Peyrot, Cyril Martin, Léonard Féasson, Pablo Bartolucci, Anoosha Habibi, Emma Guillet, Justine Gellen-Dautremer, Jean-Antoine Ribeil, Jean-Benoit Arlet, Sarah Mattioni, Jugurtha Berkenou, Noemie Delrieux, François Lionnet, Jean-François GrenotSummaryBackgroundExercise could be a triggering factor for vaso-occlusive crises in patients with sickle-cell disease. We ...
Source: The Lancet Haematology - November 1, 2018 Category: Hematology Source Type: research

Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis
In this study, we assessed the cost-effectiveness of this strategy.MethodsIDEAL DVT was a multicentre, randomised, non-inferiority trial that included patients with acute proximal deep vein thrombosis of the leg. After 6 months of elastic compression therapy, patients were randomly assigned (1:1) to the standard 2 years of elastic stocking compression therapy or shortened duration of compression therapy based on the patient's Villalta score. For our cost-effectiveness analysis, we assessed quality-adjusted life-years (QALYs), measured with the three-level version of EQ-5D (EQ-5D-3L; Dutch and UK tariff) and the 36-item Sho...
Source: The Lancet Haematology - October 10, 2018 Category: Hematology Source Type: research

Elastic compression therapy to prevent post-thrombotic syndrome
Publication date: Available online 9 October 2018Source: The Lancet HaematologyAuthor(s): Nicos Labropoulos (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 10, 2018 Category: Hematology Source Type: research

Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review
Publication date: October 2018Source: The Lancet Haematology, Volume 5, Issue 10Author(s): Huifang Lu, Anna S Lok, Carla L Warneke, Sairah Ahmed, Harrys A Torres, Fernando Martinez, Maria E Suarez-Almazor, Jessica T Foreman, Alessandra Ferrajoli, Jessica P HwangSummaryBackgroundPatients previously infected with hepatitis B virus (HBV; indicated by positivity for anti-HBc) can experience HBV reactivation during cancer chemotherapy. Intravenous immunoglobulin infusion, which is frequently used in supportive care, might facilitate passive transfer of anti-HBc. We aimed to estimate the probability of passive transfer of anti-H...
Source: The Lancet Haematology - October 5, 2018 Category: Hematology Source Type: research

Beta-thalassaemia: all roads lead to a cure?
Publication date: October 2018Source: The Lancet Haematology, Volume 5, Issue 10Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - October 5, 2018 Category: Hematology Source Type: research